Presentations & Speakers:
Value of a pre-IND interaction with the US FDA during late lead optimization: Bugworks experience
Bala Subramanian, Bugworks Research Inc.
Amicidins: Building clinical and regulatory strategies for non-traditional products to prevent and treat life-threatening infections
Michael P. Bevilacqua, Amicrobe, Inc.
Discovery and development of microbiome therapeutics using reverse translation
Matthew Henn & Chris Ford, Seres Therapeutics
Development of a multi-component toxoid vaccine for S. aureus – Regulatory challenges and opportunities
M. Javad Aman & Catherine Bernard, Integrated BioTherapeutics
Regulatory challenges for RaPID/BSI – culture-free identification and characterization of bloodstream infections
David Steinmiller, HelixBind Inc.
Moderator: Erin Duffy, CARB-X
The presentations were followed by a Q&A session.